Eli Lilly and Co (BSP:LILY34)
R$ 130.52 -2.2 (-1.66%) Market Cap: 3.72 Til Enterprise Value: 3.84 Til PE Ratio: 113.84 PB Ratio: 56.38 GF Score: 73/100

Eli Lilly and Co at Guggenheim Partners Healthcare Talks Oncology Days Transcript

Feb 12, 2021 / 04:00PM GMT
Release Date Price: R$36.97 (+1.55%)
Seamus Christopher Fernandez
Guggenheim Securities, LLC, Research Division - Senior Analyst of Global Pharmaceuticals

All right. Good morning, everyone. I believe we are now live. And this is the second day of Guggenheim's oncology days. I can't say that we can't call it the oncology day anymore because it's now a 2-day conference because there are so many companies really drilling into oncology. But I'm really pleased to be joined here today with Anne White, who you see on the screen. Anne is the Senior Vice President and President of Lilly Oncology. And also, we have Jake Van Naarden, who many of you know, Jake is CEO of Loxo Oncology, which is one of the acquired subsidiaries of Eli Lilly.

Questions & Answers

Seamus Christopher Fernandez
Guggenheim Securities, LLC, Research Division - Senior Analyst of Global Pharmaceuticals

So just to jump right in, we only have 25 minutes, so there's plenty to get to. Anne maybe just to kick us off just from a big picture strategy perspective, if you don't mind, just love to maybe start off on your thinking

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot